345 related articles for article (PubMed ID: 20385790)
1. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
Meltzer ME; Lisman T; de Groot PG; Meijers JC; le Cessie S; Doggen CJ; Rosendaal FR
Blood; 2010 Jul; 116(1):113-21. PubMed ID: 20385790
[TBL] [Abstract][Full Text] [Related]
2. [Relationship between plasma levels of thrombin activatable fibrinolysis inhibitor, plasminogen activator inhibitor-1 and tissue-type plasminogen activator and deep venous thrombosis in patients with systemic lupus erythematosus].
Liu YF; Hou N; Shi YJ; Li CX; Gao YJ; Liu LN
Zhonghua Yi Xue Za Zhi; 2023 Jun; 103(21):1638-1642. PubMed ID: 37248064
[No Abstract] [Full Text] [Related]
3. Variable Resistance to Plasminogen Activator Initiated Fibrinolysis for Intermediate-Risk Pulmonary Embolism.
Stubblefield WB; Alves NJ; Rondina MT; Kline JA
PLoS One; 2016; 11(2):e0148747. PubMed ID: 26866684
[TBL] [Abstract][Full Text] [Related]
4. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
Erem C; Kocak M; Nuhoglu I; Yilmaz M; Ucuncu O
Eur J Endocrinol; 2009 May; 160(5):863-8. PubMed ID: 19233920
[TBL] [Abstract][Full Text] [Related]
5. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
Akinci B; Comlekci A; Yener S; Demir T; Ozcan MA; Bayraktar F; Yesil S
Endocr J; 2007 Aug; 54(4):593-9. PubMed ID: 17690487
[TBL] [Abstract][Full Text] [Related]
6. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
Erem C; Nuhoglu I; Yilmaz M; Kocak M; Demirel A; Ucuncu O; Onder Ersoz H
J Endocrinol Invest; 2009 Feb; 32(2):169-74. PubMed ID: 19411818
[TBL] [Abstract][Full Text] [Related]
7. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
Chudý P; Kotuličová D; Staško J; Kubisz P
Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
[TBL] [Abstract][Full Text] [Related]
8. Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men.
Meltzer ME; Doggen CJ; de Groot PG; Rosendaal FR; Lisman T
Blood; 2010 Jul; 116(4):529-36. PubMed ID: 20413657
[TBL] [Abstract][Full Text] [Related]
9. Determinants of plasma fibrin clot lysis measured using three different assays in healthy subjects.
Siudut J; Iwaniec T; Plens K; Pieters M; Undas A
Thromb Res; 2021 Jan; 197():1-7. PubMed ID: 33157491
[TBL] [Abstract][Full Text] [Related]
10. Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome.
Hoekstra J; Guimarães AH; Leebeek FW; Darwish Murad S; Malfliet JJ; Plessier A; Hernandez-Guerra M; Langlet P; Elias E; Trebicka J; Primignani M; Garcia-Pagan JC; Valla DC; Rijken DC; Janssen HL;
Blood; 2010 Jan; 115(2):388-95. PubMed ID: 19965669
[TBL] [Abstract][Full Text] [Related]
11. Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays.
Bollen L; Peetermans M; Peeters M; Van Steen K; Hoylaerts MF; Declerck PJ; Verhamme P; Gils A
Thromb Res; 2014 Nov; 134(5):1097-102. PubMed ID: 25193405
[TBL] [Abstract][Full Text] [Related]
12. A history of early stent thrombosis is associated with prolonged clot lysis time.
Pankiw-Bembenek O; Zalewski J; Goralczyk T; Undas A
Thromb Haemost; 2012 Mar; 107(3):513-20. PubMed ID: 22274545
[TBL] [Abstract][Full Text] [Related]
13. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
Aso Y; Wakabayashi S; Yamamoto R; Matsutomo R; Takebayashi K; Inukai T
Diabetes Care; 2005 Sep; 28(9):2211-6. PubMed ID: 16123492
[TBL] [Abstract][Full Text] [Related]
14. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
Zorio E; Castelló R; Falcó C; España F; Osa A; Almenar L; Aznar J; Estellés A
Br J Haematol; 2003 Sep; 122(6):958-65. PubMed ID: 12956767
[TBL] [Abstract][Full Text] [Related]
15. Thromboembolic events are associated with prolonged clot lysis time in patients with permanent atrial fibrillation.
Ząbczyk M; Majewski J; Lelakowski J
Pol Arch Med Wewn; 2011 Nov; 121(11):400-7. PubMed ID: 22064373
[TBL] [Abstract][Full Text] [Related]
16. Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and TAFI in advanced carotid plaque.
Jönsson Rylander AC; Lindgren A; Deinum J; Bergström GM; Böttcher G; Kalies I; Wåhlander K
J Thromb Haemost; 2017 Apr; 15(4):758-769. PubMed ID: 28135035
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
Yener S; Akarsu M; Demir T; Akinci B; Sagol O; Bayraktar F; Ozcan MA; Tankurt E; Yesil S
J Endocrinol Invest; 2007 Nov; 30(10):810-9. PubMed ID: 18075282
[TBL] [Abstract][Full Text] [Related]
18. Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis.
Incampo F; Carrieri C; Galasso R; Scaraggi FA; Di Serio F; Woodhams B; Semeraro N; Colucci M
J Thromb Haemost; 2013 Feb; 11(2):315-24. PubMed ID: 23256818
[TBL] [Abstract][Full Text] [Related]
19. Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A.
Soliman M; Osman N; Hefnawy S; El Hawy MA
Pediatr Hematol Oncol; 2022 May; 39(4):318-328. PubMed ID: 34668834
[TBL] [Abstract][Full Text] [Related]
20. Fibrinolytic Changes in Women with Preeclampsia.
Godtfredsen AC; Sidelmann JJ; Dolleris BB; Jørgensen JS; Johansen EKJ; Pedersen MFB; Palarasah Y; Gram JB
Clin Appl Thromb Hemost; 2022; 28():10760296221126172. PubMed ID: 36217728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]